HMG-CoA reductase inhibitors in osteoporosis: do they reduce the risk of fracture?

摘要: Osteoporosis affects a large number of people in industrialised countries. It has clinical and public-health impacts, most importantly due to subsequent fractures. Osteoporotic fractures are one the common causes disability associated with enormous healthcare expenditure. The majority existing treatment options for osteoporosis only inhibit bone resorption prevent excessive loss but not capable stimulating formation. However, several recent vitro vivo studies animals demonstrated that HMG-CoA reductase inhibitors stimulate production morphogenetic protein (BMP-2), which is potent regulating osteoblast differentiation activity. This suggests may have an anabolic effect on bones, making them potentially interesting option osteoporosis. Additionally, humans showed some beneficial turnover lead increase mineral density. Consequently, observational tried evaluate whether use decreased risk Even though all results these epidemiological studies, using different designs study populations, were entirely consistent, they provided substantial evidence inhibitor decrease fracture by approximately 50%. On other hand, reanalyses two randomised controlled trials therapy, designed assess cardiovascular outcomes, could show patients treated had lower comparison placebo-treated patients. Therefore, conclusively potential prevention osteoporosis, need be performed address this conflicting issue. Until such available, practitioners should prescribe drugs been proven reduce osteoporotic